Medtronic's Endeavor drug-coated stent, which an FDA advisory panel recommended for approval, will still face safety concerns from regulators, doctors and patients, this analysis says. The company also recognizes it will face marketing concerns, and one executive says, "We expect there will be renewed usage of drug-eluting stents. But we don't think the market will return to its peak."

Related Summaries